US EditionPublished • loading... • Updated
Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Petco improved operating income by 83.2% to $31.9 million and reduced debt by $95 million, enhancing cash flow and lowering leverage ratio in 2025, management said.
- NFI Group Inc. announced audited consolidated Fiscal 2025 results on March 11, 2026 from Winnipeg and scheduled a conference call/webcast for analysts and investors on March 12, 2026.
- Following the settlement and new orders, recoveries from the Battery Settlement with XALT Energy, LLC, including $114.5 million net of tax, supported NFI's results and the backlog of approximately $13.0 billion.
- The company reported revenue of $1,025.1 million and Adjusted EBITDA of $121.3 million, while ROIC increased to 11.3%.
- Management said it expects Fiscal 2026 revenue to be $3.9 billion to $4.2 billion and Adjusted EBITDA of $370 million to $410 million, forecasting improvements in 2026.
- Tariff and supply-chain headwinds could raise costs as new global 10% International Emergency Economic Powers Act tariffs apply, while guidance excludes future tariff or trade-policy changes, NFI said.
Insights by Ground AI
68 Articles
68 Articles
The Billings Gazette+11 Reposted by 11 other sources
Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
SAN FRANCISCO, March 12, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2025.
·Billings, United States
Read Full Article
Coverage Details
Total News Sources68
Leaning Left14Leaning Right3Center21Last UpdatedBias Distribution55% Center
Bias Distribution
- 55% of the sources are Center
55% Center
L 37%
C 55%
Factuality
To view factuality data please Upgrade to Premium
